Akay, O. M. Et Al. 2021. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study. HEMATOLOGICAL ONCOLOGY , vol.39, no.4 , 498-505.

Akay, O. M., ÖZBALAK, M. M., PEHLİVAN, M., Yildiz, B., UZAY, A., Yigenoglu, T. N., ... ELVERDİ, T.(2021). Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study. HEMATOLOGICAL ONCOLOGY , vol.39, no.4, 498-505.

Akay, Olga Et Al. "Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study," HEMATOLOGICAL ONCOLOGY , vol.39, no.4, 498-505, 2021

Akay, Olga M. Et Al. "Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study." HEMATOLOGICAL ONCOLOGY , vol.39, no.4, pp.498-505, 2021

Akay, O. M. Et Al. (2021) . "Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study." HEMATOLOGICAL ONCOLOGY , vol.39, no.4, pp.498-505.

@article{article, author={Olga Meltem Akay Et Al. }, title={Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study}, journal={HEMATOLOGICAL ONCOLOGY}, year=2021, pages={498-505} }